semaglutide heart Study Finds Oral Vastly Reduces Attacks, Strokes Semaglutide improves heart failure symptoms

GLP-1 is an incretin hormone that enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, improving glycemic control and promoting weight loss

If symptoms persist despite these measures, consult your prescribing clinician about potential dose adjustments or alternative GLP-1 formulations, as individual responses vary between different agents in this class

However, the appetite suppression and GI side effects often outweigh potential benefits in patients with poor nutritional status or active disease, requiring careful risk-benefit assessment

GLP-1s are still relevant to the growth narrative: management disclosed $230M (39%) in Q1 2025 and $190M (35%) in Q2 2025